Oxidation of Toxic and Carcinogenic Chemicals by Human Cytochrome P-450 Enzymes

Chemical Research in Toxicology

Volumn 4, Issue 4, 1991, Pages 391-407

  Peter Guengerich, F ^a   Shimada, Tsutomu ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OSAKA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; CYTOCHROME P450; ISOENZYME;

HUMAN; OXIDATION; REVIEW;

ANIMAL; CARCINOGENS; CYTOCHROME P-450 ENZYME SYSTEM; HUMAN; ISOENZYMES; OXIDATION-REDUCTION; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025992864     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx00022a001     Document Type: Article

References (257)

1. Miller, J. A. (1970) Carcinogenesis by chemicals: An overview-G. H. A. Clowes memorial lecture. Cancer Res. 30, 559–576.
2. Mueller, G. C., and Miller, J. A. (1948) The metabolism of 4-dimethylaminoazobenzene by rat liver homogenates. J. Biol. Chem. 176, 535–544.
3. Miller, E. C. (1951) Studies on the formation of proteinbound derivatives of 3, 4-benzpyrene in the epidermal fraction of mouse skin. Cancer Res. 11, 100–108.
4. Miller, E. C., and Miller, J. A. (1981) Searches for ultimate chemical carcinogens and their reactions with cellular macromolecules. Cancer 47, 2327–2345.
5. Wood, A. W., Levin, W., Lu, A. Y. H., Yagi, H., Hernandez, O., Jerina, D. M., and Conney, A. H. (1976) Metabolism of benzo-[a]pyrene and benzo[a]pyrene derivatives to mutagenic products by highly purified hepatic microsomal enzymes. J. Biol. Chem. 251, 4882–4890.
6. Oesch, F. (1979) Epoxide hydratase. In Progress in Drug Metabolism (Bridges, J. W., and Chasseaud, L. F., Eds.) pp 253–301, John Wiley, Chichester, England.
7. Peterson, L. A., and Guengerich, F. P. (1988) Comparison of and relationships between glutathione S-transferase and cytochrome P-450 systems. In Glutathione Conjugation: Its Mechanisms and Biological Significance (Sies, H., and Ketterer, B., Eds.) pp 193–233, Academic Press, London.
8. Anders, M. W., Lash, I., Dekant, W., Elfarra, A. A., and Dohn, D. R. (1988) Biosynthesis and biotransformation of glutathione S-conjugates to toxic metabolites. CRC Crit. Reυ. Toxicol. 18, 311–341.
9. Green, M. D., and Tephly, T. R. (1987) N-Glucuronidation of carcinogenic aromatic amines catalyzed by rat hepatic microsomal preparations and purified rat liver uridine 5′-diphosphateglucuronosyltransferases. Cancer Res. 47, 2028–2031.
10. Tephley, T. R. (1990) Isolation and purification of UDP-glucuronosyltransferases. Chem. Res. Toxicol. 3, 509–516.
11. Tateishi, M., Suzuki, S., and Shimizu, H. (1978) Cysteine conjugate βlyase in rat liver: A novel enzyme catalyzing formation of thiolcontaining metabolites of drugs. J. Biol. Chem. 253, 8854–8859.
12. Boogaard, P. J., Commandeur, J. N. M., Mulder, G. J., Vermeulen, N. P. E., and Nagelkerke, J. F. (1989) Toxicity of the cysteine-S-conjugates and mercapturic acids of four structurally related difluoroethylenes in isolated proximal tubular cells from rat kidney: Uptake of the conjugates and activation to toxic metabolites. Biochem. Pharmacol. 38, 3731–3741.
13. Ziegler, D. M., Ansher, S. S., Nagata, T., Kadlubar, F. F., and Jakoby, W. B. (1988) N-Methylation: Potential mechanism for metabolic activation of carcinogenic primary arylamines. Proc. Natl. Acad. Sci. U.S.A. 85, 2514–2517.
14. Jakoby, W. B., Ed. (1980) Enzymatic Basis of Detoxication, Vols. 1 and 2, Academic Press, New York.
15. Ohno, Y., Ormstad, K., Ross, D., and Orrenius, S. (1985) Mechanism of allyl alcohol toxicity and protective effects of lowmolecularweight thiols studied with isolated rat hepatocytes. Toxicol. Appl. Pharmacol. 78, 169–179.
16. Chiba, K., Peterson, L. A., Castagnoli, K. P., Trevor, A. J., and Castagnoli, N., Jr. (1985) Studies on the molecular mechanism of bioactivation of the selective nitrostriatal toxin 1-methyl-4-phenyll, 2, 3, 6-tetrahydropyridine. Drug Metab. Dispos. 13, 342–347.
17. Ziegler, D. M. (1988) Flavincontaining monooxygenases: Catalytic mechanism and substrate specificities. Drug Metab. Reυ. 19, 1–32.
18. Reed, G. A., and Marnett, L. J. (1982) Metabolism and activation of 7, 8-dihydrobenzo[α]pyrene during prostaglandin biosynthesis: Intermediacy of a bayregion epoxide. J. Biol. Chem. 257, 11368–11376.
19. Kadlubar, F. F., Miller, J. A., and Miller, E. C. (1976) Microsomal N-oxidation of the hepatocarcinogen N-methyl-4-aminoazobenzene and the reactivity of N-hydroxy-N-methyl-4-aminoazobenzene. Cancer Res. 36, 1196–1206.
20. 2-aminofluorenyl)-deoxyguanosine-3′, 5′-diphosphate from 2-aminofluorene. Carcinogenesis 11, 1441–1444.
21. Guengerich, F. P., and Liebler, D. C. (1985) Enzymatic activation of chemicals to toxic metabolites. CRC Crit. Rev. Toxicol. 14, 259–307.
22. Kadlubar, F. F., and Hammons, G. J. (1987) The role of cytochrome P-450 in the metabolism of chemical carcinogens. In Mammalian Cytochromes P-450 (Guengerich, F. P., Ed.) Vol. 2, pp 81–130, CRC Press, Boca Raton, FL.
23. Guengerich, F. P. (1990) Enzymatic oxidation of xenobiotic chemicals. Crit. Reυ. Biochem. Mol. Biol. 25, 97–153.
24. Guengerich, F. P., and Macdonald, T. L. (1990) Mechanisms of cytochrome P-450 catalysis. FASEB J. 4, 2453–2459.
25. 6-ethenoadenosine. Chem. Res. Toxicol, (in press).
26. Mico, B. A., and Pohl, L. R. (1983) Reductive oxygenation of carbon tetrachloride: Trichloromethylperoxyl radical as a possible intermediate in the conversion of carbon tetrachloride to electrophilic chlorine. Arch. Biochem. Biophys. 225, 596–609.
27. Busby, W. F., Jr., Wang, J. S., Stevens, E. K., Padykula, R. E., Aleksejczyk, R. A., and Berchtold, G. A. (1990) Lung tumorigenicity of benzene oxide, benzene dihydrodiols and benzene diolepoxides in the BLU;Ha newborn mouse assay. Carcinogenesis 11, 1473–1478.
28. Witz, G., Latriano, I., and Goldstein, B. D. (1989) Metabolism and toxicity of trans, transmuconaldehyde, an openring microsomal metabolite of benzene. Enυiron. Health Perspect. 82, 19–22.
29. Ortiz de Montellano, P. R., Ed. (1986) Cytochrome P-450, Plenum Press, New York.
30. Nebert, D. W., Nelson, D. R., Adesnik, M., Coon, M. J., Estabrook, R. W., Gonzalez, F. J., Guengerich, F. P., Gunsalus, I. C., Johnson, E. F., Kemper, B., Levin, W., Phillips, I., Sato, R., and Waterman, M. (1989) The P450 superfamily: Updated listing of all genes and recommended nomenclature for the chromosomal loci. DNA 8, 1–13.
31. Gonzalez, F. J. (1990) Molecular genetics of the P-450 superfamily. Pharmacol. Ther. 45, 1–38.
32. Parandoosh, Z., Fujita, V. S., Coon, M. J., and Philpot, R. M. (1987) Cytochrome P-450 isozymes 2 and 5 in rabbit lung and liver: Comparisons of structure and inducibility. Drug Metab. Dispos. 15, 59–67.
33. Vanderslice, R. R., Domin, B. A., Carver, G. T., and Philpot, R. M. (1987) Speciesdependent expression and induction of homologues of rabbit cytochrome P-450 isozyme 5 in liver and lung. Mol. Pharmacol. 31, 320–325.
34. Masters, B. S. S., Muerhoff, A. S., and Okita, R. T. (1987) Enzymology of extrahepatic cytochromes P-450. In Mammalian Cytochromes P-450 (Guengerich, F. P., Ed.) pp 107–131, CRC Press, Boca Raton, FL.
35. Johnson, E. F., Walker, D. I., Griffin, K. J., Clark, J. E., Okita, R. T., Muerhoff, A. S., and Masters, B. S. (1990) Cloning and expression of three rabbit kidney cDNAs encoding lauric acid ωhydroxylases. Biochemistry 29, 873–879.
36. Fujisawa-Sehara, A., Yamane, M., and Fujii-Kuriyama, Y. (1988) A DNA-binding factor specific for xenobiotic responsive elements of P-450c gene exists as a cryptic form in cytoplasm: Its possible translocation to nucleus. Proc. Natl. Acad. Sci. U.S.A. 85, 5859–5863.
37. Whitlock, J. P., Jr. (1990) Genetic and molecular aspects of 2, 3, 7, 8-tetrachlorodibenzop-dioxin action. Annu. Reυ. Pharmacol. Toxicol. 30, 251–277.
38. Fisher, J. M., Wu, I., Denison, M. S., and Whitlock, J. P., Jr. (1990) Organization and function of a dioxinresponsive enhancer. J. Biol. Chem. 265, 9676–9681.
39. Waterman, M. R., Mason, J. I., Zuber, M. X., John, M. E., Rodgers, R. J., and Simpson, E. R. (1986) Control of gene expression of adrenal steroid hydroxylases and related enzymes. Endoer. Res. 12, 393–408.
40. Niranjan, B. G., Avadhani, N. G., and DiGiovanni, J. (1985) Formation of benzo(α)pyrene metabolites and DNA adducts catalyzed by a rat liver mitochondrial monooxygenase system. Blochern. Biophys. Res. Commun. 131, 935–942.
41. 1 and benzo(a)pyrene. J. Biol. Chem. 259, 12495–12501.
42. 1 metabolism. Biochemistry 28, 7546–7554.
43. Guengerich, F. P. (1988) Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Res. 48, 2946–2954.
44. Guengerich, F. P. (1990) Characterization of roles of human cytochrome P-450 enzymes in carcinogen metabolism. Asia Pacific J. Pharmacol. 5, 327–345.
45. Nebert, D. W. (1978) Genetic control of carcinogen metabolism leading to individual differences in cancer risk. Biochimie 60, 1019–1029.
46. Nebert, D. W. (1989) The Ah locus: Genetic differences in toxicity, cancer, mutation, and birth defects. Chem. Res. Toxicol. 2, 153–174.
47. Nebert, D. W. (1981) Genetic differences in susceptibility to chemically induced myelotoxicity and leukemia. Environ. Health Perspect. 39, 11–22.
48. Levitt, R. C., Fysh, J. M., Jensen, N. M., and Nebert, D. W. (1979) The Ah locus: Biochemical basis for genetic differences in brain tumor formation in mice. Genetics 92, 1205–1210.
49. Bradley, M. O., Bhuyan, B., Francis, M. C., Langenbach, R., Peterson, A., and Huberman, E. (1981) Mutagenesis by chemical agents in V79 Chinese hamster cells: A review and analysis of the literature. Mutat. Res. 87, 81–142.
50. Shimada, T., Iwasaki, M., Martin, M. V., and Guengerich, F. P. (1989) Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA1535/pSK1002. Cancer Res. 49, 3218–3228.
51. Aoyama, T., Gelboin, H. V., and Gonzalez, F. J. (1990) Mutagenic activation of 2-amino-3-methylimidazo[4, 5-f]quinoline by complementary DNA-expressed human liver P-450. Cancer Res. 50, 2060–2063.
52. Distlerath, L. M., and Guengerich, F. P. (1987) Enzymology of human liver cytochromes P-450. In Mammalian Cytochromes P-450 (Guengerich, F. P., Ed.) Vol. 1, pp 133–198, CRC Press, Boca Raton, FL.
53. Küpfer, A., and Preisig, R. (1983) Inherited defects of hepatic drug metabolism. Semin. Liver Dis. 3, 341–354.
54. Eichelbaum, M. (1984) Polymorphic drug oxidation in humans. Fed. Proc. 43, 2298–2302.
55. Smith, R. L. (1988) The role of metabolism and disposition studies in the safety assessment of pharmaceuticals. Xenobiotica 18, 89–96.
56. Idle, J. R., and Smith, R. L. (1979) Polymorphisms of oxidation at carbon centers of drugs and their clinical significance. Drug Metab. Rev. 9, 301–317.
57. Guengerich, F. P., and Turvy, C. G. (1991) Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J. Pharmacol. Exp. Ther. 256, 1189–1194.
58. Guengerich, F. P. (1990) Metabolism of 17 αethynylestradiol in humans. Life Sci. 47, 1981–1988.
59. Peterson, L. A., Carmella, S. G., and Hecht, S. S. (1990) Investigations of metabolic precursors to hemoglobin and DNA adducts of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis 11, 1329–1333.
60. Lennard, M. S., Ramsay, L. E., Silas, J. H., Tucker, G. T., and Woods, H. F. (1983) Protecting the poor metabolizer: Clinical consequences of genetic polymorphism of drug oxidation. Pharm. Int. 4, 61–65.
61. Ayesh, R., Idle, J. R., Ritchie, J. C., Crothers, M. J., and Hetzel, M. R. (1984) Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 312, 169–170.
62. Kaisary, A., Smith, P., Jaczq, E., McAllister, C. B., Wilkinson, G. R., Ray, W. A., and Branch, R. A. (1987) Genetic predisposition to bladder cancer: Ability to hydroxylate debrisoquine and mePhenytoin as risk factors. Cancer Res. 47, 5488–5493.
63. Caporaso, N., Hayes, R. B., Dosemeci, M., Hoover, R., Ayesh, R., Hetzel, M., and Idle, J. (1989) Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype. Cancer Res. 49, 3675–3679.
64. Kaschnitz, R. M., and Coon, M. J. (1975) Drug and fatty acid hydroxylation by solubilized human liver microsomal cytochrome P-450 phospholipid requirement. Biochem. Pharmacol. 24, 295–297.
65. Beaune, P., Dansette, P., Flinois, J. P., Columelli, S., Mansuy, D., and Leroux, J. P. (1979) Partial purification of human liver cytochrome P-450. Biochem. Biophys. Res. Commun. 88, 826–832.
66. Kitada, M., and Kamataki, T. (1979) Partial purification and properties of cytochrome P450 from homogenates of human fetal livers. Biochem. Pharmacol. 28, 793–797.
67. Wang, P., Mason, P. S., and Guengerich, F. P. (1980) Purification of human liver cytochrome P-450 and comparison to the enzyme isolated from rat liver. Arch. Biochem. Biophys. 199, 206–219.
68. Guengerich, F. P., Wang, P., Mason, P. S., and Mitchell, M. B. (1981) Immunological comparison of rat, rabbit, and human microsomal cytochromes P-450. Biochemistry 20, 2370–2378.
69. Wang, P. P., Beaune, P., Kaminsky, L. S., Dannan, G. A., Kadlubar, F. F., Larrey, D., and Guengerich, F. P. (1983) Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes. Biochemistry 22, 5375–5383.
70. Shimada, T., Misono, K. S., and Guengerich, F. P. (1986) Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction. J. Biol. Chem. 261, 909–921.
71. Watkins, P. B., Wrighton, S. A., Maurel, P., Schuetz, E. G., Mendez-Picon, G., Parker, G. A., and Guzelian, P. S. (1985) Identification of an inducible form of cytochrome P-450 in human liver. Proc. Natl. Acad. Sci. U.S.A. 82, 6310–6314.
72. Wrighton, S. A., Thomas, P. E., Willis, P., Maines, S. I., Watkins, P. B., Levin, W., and Guzelian, P. S. (1987) Purification of a human liver cytochrome P-450 immunochemically related to several cytochromes P-450 purified from untreated rate. J. Clin. Invest. 80, 1017–1022.
73. Wrighton, S. A., Thomas, P. E., Ryan, D. E., and Levin, W. (1987) Purification and characterization of ethanolinducible human hepatic cytochrome P-450HLj. Arch. Biochem. Biophys. 258, 292–297.
74. Distlerath, L. M., Reilly, P. E. B., Martin, M. V., Davis, G. G., Wilkinson, G. R., and Guengerich, F. P. (1985) Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 260, 9057–9067.
75. Guengerich, F. P., Martin, M. V., Beaune, P. H., Kremers, P., Wolff, T., and Waxman, D. J. (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261, 5051–5060.
76. Ged, C., Umbenhauer, D. R., Bellew, T. M., Bork, R. W., Srivastava, P. K., Shinriki, N., Lloyd, R. S., and Guengerich, F. P. (1988) Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450(S)-mephenytoin 4′-hydroxylase. Biochemistry 27, 6929–6940.
77. Srivastava, P. K., Yun, C.-H., Beaune, P. H., Ged, C., and Guengerich, F. P. (1991) Separation of human liver tolbutamine hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes. Mol. Pharmacol, (in press).
78. Gut, J., Meier, U. T., Catin, T., and Meyer, U. A. (1986) Mephenytointype polymorphism drug oxidation: Purification and characterization of a human liver cytochrome P-450 isozyme catalyzing microsomal mephenytoin hydroxylation. Biochim. Biophys. Acta 884, 435–447.
79. Gut, J., Catin, T., Dayer, P., Kronbach, T., Zanger, U., and Meyer, U. A. (1986) Debrisoquine/sparteinetype polymorphism of drug oxidation: Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol. J. Biol. Chem. 261, 11734–11743.
80. Butler, M. A., Iwasaki, M., Guengerich, F. P., and Kadlubar, F. F. (1989) Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. U.S.A. 86, 7696–7700.
81. Wrighton, S. A., Ring, B. J., Watkins, P. B., and Vandenbranden, M. (1989) Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol. Pharmacol. 86, 97–105.
82. Beaune, P. H., Umbenhauer, D. R., Bork, R. W., Lloyd, R. S., and Guengerich, F. P. (1986) Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase. Proc. Natl. Acad. Sci. U.S.A. 83, 8064–8068.
83. Umbenhauer, D. R., Martin, M. V., Lloyd, R. S., and Guengerich, F. P. (1987) Cloning and sequence determination of a complementary DNA related to human liver microsomal cytochrome P-450 S-mephenytoin 4-hydroxylase. Biochemistry 26, 1094–1099.
84. Kimura, S., Pastewka, J., Gelboin, H. V., and Gonzalez, F. J. (1987) cDNA and amino acid sequences of two members of the human P450IIC gene subfamily. Nucleic Acids Res. 15, 10053.
85. Yamano, S., Nagata, K., Yamazoe, Y., Kato, R., Gelboin, H. V., and Gonzalez, F. J. (1989) cDNA and deduced amino acid sequences of human P450 IIA3 (CYP2A3). Nucleic Acids Res. 17, 4888.
86. Nhamburo, P. T., Gonzalez, F. J., McBride, O. W., Gelboin, H. V., and Kimura, S. (1989) Identification of a new P450 expressed in human lung: Complete cDNA sequence, cDNA-directed expression, and chromosome mapping. Biochemistry 28, 8060–8066.
87. Reeck, G. R., de Haën, C., Teller, D. C., Doolittle, R. F., Fitch, W. M., Dickerson, R. E., Chambon, P., McLachlan, A. D., Margoliash, E., Jukes, T. H., and Zuckerkandl, E. (1987) “Homology” in proteins and nucleic acids: A terminology muddle and a way out of it. Cell 50, 667.
88. Lewin, R. (1987) When does homologoy means something else? Science 237, 1570.
89. Petrelle, R. J., and Yokoyama, M. M. (1990) Ubihomologous homology usage. Nature 343, 518.
90. Aoyama, T., Yamano, S., Waxman, D. J., Lapenson, D. P., Meyer, U. A., Fischer, V., Tyndale, R., Inaba, T., Kalow, W., Gelboin, H. V., and Gonzalez, F. J. (1989) Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. J. Biol. Chem. 264, 10388–10395.
91. Guengerich, F. P. (1989) Characterization of human microsomal cytochrome P-450 enzymes. Annu. Reυ. Pharmacol. Toxicol. 29, 241–264.
92. Shimada, T., Martin, M. V., Pruess-Schwartz, D., Marnett, L. J., and Guengerich, F. P. (1989) Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo(α)pyrene, 7, 8-dihydroxy-7, 8-dihydrobenzo(α)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons. Cancer Res. 49, 6304–6312.
93. McManus, M. E., Burgess, W. M., Veronese, M. E., Huggett, A., Quattrochi, L. C., and Tukey, R. H. (1990) Metabolism of 2-acetylaminofluorene and benzo(α)pyrene and activation of foodderived heterocyclic amine mutagens by human cytochromes P-450. Cancer Res. 50, 3367–3376.
94. Gonzalez, F. J., Aoyama, T., and Gelboin, H. V. (1990) Activation of promutagens by human cDNA-expressed cytochrome P450s. In Mutation and the Environment, Part B: Metabolism, Testing Methods, and Chromosomes (Mendelshon, M. I., and Albertini, R. J., Eds.) pp 77–86, Wiley-Liss, New York.
95. Ohta, K., Kitada, M., Ohi, H., Komori, M., Nagashima, K., Sato, N., Muroya, K., Kodama, T., Nagao, M., and Kamataki, T. (1989) Interspecies homology of cytochrome P-450: Toxicological significance of cytochrome P-450 crossreactive with antirat P-448-H antibodies in liver microsomes from dogs, monkeys and humans. Mutat. Res. 226, 163–167.
96. ı and 2-amino-3-methylimidazo[4, 5-f]-quinoline by human adult and fetal livers. Cancer Res. 50, 2641–2645.
97. Yamazoe, Y., Abu-Zeid, M., Yamauchi, K., and Kato, R. (1988) Metabolic activation of pyrolysate arylamines by human liver microsomes: Possible involvement of P-448-H type cytochrome P-450. Jpn. J. Cancer Res. 79, 1159–1167.
98. Raucy, J. I., Lasker, J. M., Lieber, C. S., and Black, M. (1989) Acetaminophen activation by human liver cytochrome P450IIE1 and P450IA2. Arch. Biochem. Biophys. 271, 270–283.
99. Crespi, C. I., Penman, B. W., Leakey, J. A., Arlotto, M. P., Stark, A., Parkinson, A., Turner, T., Steimel, D. T., Rudo, K., Davies, R. I., and Langenbach, R. (1990) Human cytochrome P450IIA3;cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1. Carcinogenesis 11, 1293–1300.
100. Guengerich, F. P., Kim, D.-H., and Iwasaki, M. (1991) Role of human cytochrome P-450 IIE1 in the oxidation of several low molecular weight cancer suspects. Chem. Res. Toxicol. 4, 168–179.
101. Wrighton, S. A., Thomas, P. E., Molowa, D. T., Haniu, M., Shively, J. E., Maines, S. I., Watkins, P. B., Parker, G., Mendez-Picon, G., Levin, W, and Guzelian, P. S. (1986) Characterization of ethanolinducible human liver N-nitrosodimethylamine demethylase. Biochemistry 25, 6731–6735.
102. Yoo, J. S. H., Guengerich, F. P., and Yang, C. S. (1988) Metabolism of N-nitrosodialkylamines by human liver microsomes. Cancer Res. 48, 1499–1504.
103. Ekström, G., von Bahr, C., and Ingelman-Sundberg, M. (1989) Human liver microsomal cytochrome P-450IIE1. Immunological evaluation of its contribution to microsomal ethanol oxidation, carbon tetrachloride reduction and NADPH oxidase activity. Biochem. Pharmacol. 38, 689–693.
104. Reitz, R. H., Mendrala, A., and Guengerich, F. P. (1989) In vitro metabolism of methylene chloride in human and animal tissues: Use in physiologicallybased pharmacokinetic models. Toxicol. Appl. Pharmacol. 97, 230–246.
105. NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc. Natl. Acad. Sci. U.S.A. 86, 462–465.
106. 7 adducts and inducing different genetic responses. Chem. Res. Toxicol. 2, 114–122.
107. Brian, W. R, Sari, M.-A., Iwasaki, M., Shimada, T., Kaminsky, L. S., and Guengerich, F. P. (1990) Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cereυisiae. Biochemistry 29, 11280–11292.
108. ı. Proc. Natl. Acad. Sci. U.S.A. 87, 4790–4793.
109. 1 metabolism in human liver. Proc. Natl. Acad. Sci. U.S.A. 87, 8306–8310.
110. Miranda, C. I., Reed, R. I., Guengerich, F. P., and Buhler, D. R. (1991) Role of cytochrome P450IIIA4 in the metabolism of the pyrrolizidine alkaloid senecionine in human liver. Carcinogenesis 12, 515–519.
111. Howard, P. C., Aoyama, T., Bauer, S. I., Gelboin, H. V., and Gonzalez, F. J. (1990) The metabolism of 1-nitropyrene by human cytochromes P450. Carcinogenesis 11, 1539–1542.
112. 1 as a detoxication product. Chem. Res. Toxicol, (in press).
113. 1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 11, 2275–2279.
114. Shimada, T., Yamazaki, H., Shimura, H., Tanaka, R., and Guengerich, F. P. (1990) Metabolic deactivation of furylfuramide by cytochrome P450 in human and rat liver microsomes. Carcinogenesis 11, 103–110.
115. Shimada, T., and Guengerich, F. P. (1990) Inactivation of 1, 3-, 1, 6-, and 1, 8-dinitropyrene by human and rat microsomes. Cancer Res. 50, 2036–2043.
116. 1. Mol. Carcinog. 3, 5–8.
117. Beaune, P., Kremers, P. G., Kaminsky, L. S., de Graeve, J., and Guengerich, F. P. (1986) Comparison of monooxygenase activities and cytochrome P-450 isozyme concentrations in human liver microsomes. Drug Metab. Dispos. 14, 437–442.
118. Guengerich, F. P., Brian, W. R., Iwasaki, M., Sari, M.-A., Bäärnhielm, C., and Berntsson, P. (1991) Oxidation of dihydropyridine calcium channel blockers and analogs by human liver cytochrome P-450 IIA4. J. Med. Chem. (in press).
119. Wold, S., Albano, C., Dunn, W. J., III, Edlund, U., Esbenen, K., Geladi, P., Hellberg, S., Johansson, E., Lindberg, W., and Sjöström, M. (1984) Multivariate data analysis in chemistry. In Chemometrics, Mathematics and Statistics in Chemistry (Kowalski, B. R., Ed.) pp 17–95, D. Reidel Publishing Co., Dordrecht, Holland.
120. Thomas, P. E., Lu, A. Y. H., West, S. B., Ryan, D., Miwa, G. T., and Levin, W. (1977) Accessibility of cytochrome P450 in microsomal membranes: Inhibition of metabolism by antibodies to cytochrome P450. Mol. Pharmacol. 13, 819–831.
121. Park, S. S., Fujino, T., West, D., Guengerich, F. P., and Gelboin, H. V. (1982) Monoclonal antibodies that inhibit enzyme activity of 3-methylcholanthreneinduced cytochrome P-450. Cancer Res. 42, 1798–1808.
122. Fujino, T., Park, S. S., West, D., and Gelboin, H. V. (1982) Phenotyping of cytochromes P-450 in human tissues with monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 79, 3682–3686.
123. Park, S. S., Waxman, D. J., Miller, H., Robinson, R., Attisano, C., Guengerich, F. P., and Gelboin, H. V. (1986) Preparation and characterization of monoclonal antibodies to pregnenolone-16αcarbonitrile inducible rat liver cytochrome P-450. Biochem. Pharmacol. 35, 2859–2867.
124. Ogishima, T., Deguchi, S., and Okuda, K. (1987) Purification and characterization of cholesterol 7αhydroxylase from rat liver microsomes. J. Biol. Chem. 262, 7646–7650.
125. Zanger, U. M., Vibois, F., Hardwick, J. P., and Meyer, U. A. (1988) Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry 27, 5447–5454.
126. Pompon, D., and Nicolas, A. (1989) Protein engineering by cDNA recombination in yeasts: Shuffling of mammalian cytochrome P-450 functions. Gene 83, 15–24.
127. Elshourbagy, N. A., and Guzelian, P. S. (1980) Separation, purification, and characterization of a novel form of hepatic cytochrome P-450 from rats treated with pregnenolonel6αcarbonitrile. J. Biol. Chem. 255, 1279–1285.
128. Schwab, G. E., Raucy, J. I., and Johnson, E. F. (1988) Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by αnaphthoflavone. Mol. Pharmacol. 33, 493–499.
129. p (IIIA1). Arch. Biochem. Biophys. 277, 166–180.
130. Kaminsky, L. S., Guengerich, F. P., Dannan, G. A., and Aust, S. D. (1983) Comparisons of warfarin metabolism by liver microsomes of rats treated with a series of polybrominated biphenyl congeners and by the componentpurified cytochrome P-450 isozymes. Arch. Biochem. Biophys. 225, 398–404.
131. Porter, T. D., Pernecky, S. J., Larson, J. R., Fujita, V. S., and Coon, M. J. (1990) Expression of cytochrome P-450 in yeast and Escherichia coli. In Drug Metabolizing Enzymes: Genetics, Regulation and Toxicology, Proceedings of the Eighth International Symposium on Microsomes and Drug Oxidations (Ingelman-Sundberg, M., Gustafsson, J.-Å., and Orrenius, S., Eds.) p 20, Karolinska Institute, Stockholm.
132. Guengerich, F. P., Brian, W. R., Sari, M.-A., and Ross, J. T. (1991) Expression of mammalian cytochrome P-450 enzymes using yeastbased vectors. Methods Enzymol. (in press).
133. Zuber, M. X., Simpson, E. R., and Waterman, M. R. (1986) Expression of bovine 17αhydroxylase cytochrome P-450 cDNA in nonsteroidogenic (COS 1) cells. Science 234, 1258–1261.
134. 3-450 DNA coding sequences as enzymatically active cytochromes P-450 in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 84, 4073–4077.
135. Crespi, C. I., Langenbach, R., Rudo, K., Chen, Y. T., and Davies, R. L. (1989) Transfection of a human cytochrome P-450 gene into the human lymphoblastoid cell line, AHH-1, and use of the recombinant cell line in gene mutation assays. Carcinogenesis 10, 295–301.
136. Crespi, C. I., Langenbach, R., and Penman, B. W. (1990) The development of a panel of human cell lines expressing specific human cytochrome P450 cDNAs. In Mutation and the Environment, Part B: Metabolism, Testing Methods, and Chromosomes (Mendelsohn, M. I., and Albertini, R. J., Eds.) pp 97–106, Wiley-Liss, New York.
137. 1 metabolism by 3-methylcholanthreneinduced hamster hepatic cytochrome P-450s. J. Biochem. Toxicol. 5, 147–153.
138. 1-4-hydroxylase. J. Biol. Chem. 263, 12187–12189.
139. 1 metabolism in human liver microsomes by naturally occurring flavonoids. Cancer Res. 41, 67–72.
140. ı 8, 9-oxide with glutathione by rat and human glutathione 5-transferases. Chem. Res. Toxicol, (in press).
141. Beaune, P. H., and Guengerich, F. P. (1988) Human drug metabolism in vitro. Pharmacol. Ther. 37, 193–211.
142. Wilkinson, G. R., Guengerich, F. P., and Branch, R. A. (1989) Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol. Ther. 43, 53–76.
143. Kolars, J., Schmiedelin-Ren, P., Dobbins, W., Merion, R., Wrighton, S., and Watkins, P. (1990) Heterogeneity of P-450 IIIA expression in human gut epithelia. FASEB J. 4, A2242.
144. Watkins, P. B., Hamilton, T. A., Annesley, T. M., Ellis, C. N., Kolars, J. C., and Voorhees, J. J. (1990) The erythromycin breath test as a predictor of cyclosporine blood levels. Clin. Pharmacol. Ther. 48, 120–129.
145. Quattrochi, L. C., Okino, S. T., Pendurthi, U. R., and Tukey, R. H. (1985) Cloning and isolation of human cytochrome P-450 cDNAs homologous to dioxininducible rabbit mRNAs encoding P-450 4 and P-450 6. DNA 4, 395–400.
146. Wrighton, S. A., Campanile, C., Thomas, P. E., Maines, S. I., Watkins, P. B., Parker, G., Mendez-Picon, G., Haniu, M., Shively, J. E., Levin, W., and Guzelian, P. S. (1986) Identification of a human liver cytochrome P-450 homologous to the major isosafroleinducible cytochrome P-450 in the rat. Mol. Pharmacol. 29, 405–410.
147. 3-450: CDNA and complete protein sequence, repetitive Alu sequences in the 3′ nontranslated region, and localization of gene to chromosome 15. J. Exp. Pathol. 3, 1–17.
148. Sesardic, D., Boobis, A. R., and Davies, D. S. (1989) Tissue specific inducibility of members of the cytochrome P450IA gene subfamily in rat and man. In Xenobiotic Metabolism and Disposition, Second International Meeting, International Society for the Study of Xenobiotics (Cayen, R., Estabrook, R. W., and Kato, R., Eds.) pp 45–52, Taylor and Francis, London.
149. Brian, W. R., Srivastava, P. K., Umbenhauer, D. R., Lloyd, R. S., and Guengerich, F. P. (1989) Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 28, 4993–4999.
150. Inaba, T., Jurima, M., Mahon, W. A., and Kalow, W. (1985) In vitro inhibition studies of two isozymes of human liver cytochrome P-450: Mephenytoin phydroxylase and sparteine monooxygenase. Drug Me tab. Dispos. 13, 443–448.
151. Pessayre, D., Tinel, M., Larrey, D., Cobert, B., Funck-Brentano, C., and Babany, G. (1983) Inactivation of cytochrome P-450 by a troleandomycin metabolite. Protective role of glutathione. J. Pharmacol. Exp. Ther. 224, 685–691.
152. Guengerich, F. P. (1990) Mechanismbased inactivation of human liver cytochrome P-450 IIIA4 by gestodene. Chem. Res. Toxicol. 3, 363–371.
153. Kuhl, H., Jung-Hoffmann, C., and Heidt, F. (1988) Alterations in the serum levels of gestodene and SHBG during 12 cycles of treatment with 30 µg ethinylestradiol and 75 µg gestodene. Contraception 38, 477–486.
154. Jung-Hoffmann, C., and Kuhl, H. (1990) Interaction with the pharmacokinetics of ethinylestradiol of progestogens contained in oral contraceptives. Contraception 40, 299–312.
155. Tinel, M., Descatoire, V., Larrey, D., Loeper, J., Labbe, G., Letteron, P., and Pessayre, D. (1989) Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. J. Pharmacol. Exp. Ther. 250, 746–751.
156. Sesardic, D., Boobis, A. R., Edwards, R. J., and Davies, D. S. (1988) A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br. J. Clin. Pharmacol. 26, 363–372.
157. Fleming, C. M., Branch, R. A., Wilkinson, G. R., and Guengerich, F. P. (1990) Human liver microsomal N-hydroxylation of dapsone by cytochrome P-450 IIIA4. Pharmacologist 32, 140.
158. Yamazoe, Y., Shimada, M., Maeda, K., Kamataki, T., and Kato, R. (1984) Specificity of four forms of cytochrome P-450 in the metabolic activation of several aromatic amines and benzo-[α]pyrene. Xenobiotica 14, 549–552.
159. Djuric, Z., Potter, D. W., Heflich, R. H., and Beland, F. A. (1986) Aerobic and anaerobic reduction of nitrated pyrenes in vitro. Chem.-Biol. Interact. 59, 309–324.
160. Bourdi, M., Larrey, D., Nataf, J., Berunau, J., Pessayre, D., Iwasaki, M., Guengerich, F. P., and Beaune, P. H. (1990) A new antiliver endoplasmic reticulum antibody directed against human cytochrome P-450 IA2: A specific marker of dihydralazineinduced hepatitis. J. Clin. Invest. 85, 1967–1973.
161. Kadlubar, F. F., Talaska, G., Butler, M. A., Teitel, C. H., Masseng III, J. P., and Lang, N. P. (1990) Determination of carcinogenic arylamine N-oxidation phenotype in humans by analysis of caffeine urinary metabolites. In Mutation and the Environment, Part B: Metabolism, Testing Methods, and Chromosomes (Mendelsohn, M. I., and Albertini, R. J., Eds.) pp 107–114, Wiley-Liss, New York.
162. Yamano, S., Tatsuno, J., and Gonzalez, F. J. (1990) The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29, 1322–1329.
163. Relling, M. V., Aoyama, T., Gonzalez, F. J., and Meyer, U. A. (1990) Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J. Pharmacol. Exp. Ther. 252, 442–447.
164. Eichelbaum, M., Spannbrucker, N., Steincke, B., and Dengler, H. J. (1979) Defective N-oxidation of sparteine in man: A new pharmacogenetic defect. Eur. J. Clin. Pharmacol. 16, 183–187.
165. Küpfer, A., Schmid, B., Preisig, R., and Pfaff, G. (1984) Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet, 517–518.
166. Peter, R., Böcker, R. G., Beaune, P. H., Iwasaki, M., Guengerich, F. P., and Yang, C.-S. (1990) Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450 IIE1. Chem. Res. Toxicol. 3, 566–573.
167. Watkins, P. B., Murray, S. A., Winkelman, L. G., Heuman, D. M., Wrighton, S. A., and Guzelian, P. S. (1989) Erythromycin breath test as an assay of glucocorticoidinducible liver cytochrome P-450: Studies in rats and patients. J. Clin. Invest. 83, 688–697.
168. Bargetzi, M. J., Aoyama, T., Gonzalez, F. J., and Meyer, U. A. (1989) Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin. Pharmacol. Ther. 46, 521–527.
169. Imaoka, S., Enomoto, K., Oda, Y., Asada, A., Fujimori, M., Shimada, T., Fujita, S., Guengerich, F. P., and Funae, Y. (1990) Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: Comparison of those with rat hepatic cytochrome P-450s. J. Pharmacol. Exp. Ther. 255, 1385–1391.
170. Ged, C., Rouillon, J. M., Pichard, I., Combalbert, J., Bressot, N., Bories, P., Michel, H., Beaune, P., and Maurel, P. (1989) The increase in urinary excretion of 6|8-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br. J. Clin. Pharmacol. 28, 373–387.
171. Conney, A. H. (1982) Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G. H. A. Clowes memorial lecture. Cancer Res. 42, 4875–4917.
172. Pantuck, E. J., Hsiao, K.-C, Maggio, A., Nakamura, K., Kuntzman, R., and Conney, A. H. (1974) Effect of cigarette smoking on phenacetin metabolism. Clin. Pharmacol. Ther. 15, 9–17.
173. Diaz, D., Fabre, I., Daujat, M., Saintaubert, B., Bories, P., Michel, H., and Maurel, P. (1990) Omeprazole is an aryl hydrocarbonlike inducer of human hepatic cytochrome-P450. Gastroenterology 99, 737–747.
174. Veronese, M. E., McLean, S., D’Souza, C. A., and Davies, N. W. (1985) Formation of reactive metabolites of phenacetin in humans and rats. Xenobiotica 15, 929–940.
175. Ryan, D. E., Ramanathan, I., Iida, S., Thomas, P. E., Haniu, M., Shively, J. E., Lieber, C. S., and Levin, W. (1985) Characterization of a major form of rat hepatic microsomal cytochrome P-450 induced by isoniazid. J. Biol. Chem. 260, 6385–6393.
176. Yang, C. S., Koop, D. R., Wang, T., and Coon, M. J. (1985) Immunochemical studies on the metabolism of nitrosamines by ethanol-inducible cytochrome P-450. Biochem. Biophys. Res. Commun. 128, 1007–1013.
177. Lai, D. Y., Myers, S. C., Woo, Y. T., Greene, E. J., Friedman, M. A., Argus, M. F., and Arcos, J. C. (1979) Role of dimethylnitrosaminedemethylase in the metabolic activation of dimethylnitrosamine. Chem.-Biol. Interact. 28, 107–126.
178. 5 Arch. Biochem. Biophys. 248, 158–165.
179. Thomas, P. E., Bandiera, S., Maines, S. I., Ryan, D. E., and Levin, W. (1987) Regulation of cytochrome P-450j, a high-affinity N-nitrosodimethylamine demethylase, in rat hepatic microsomes. Biochemistry 26, 2280–2289.
180. Yang, C. S., Yoo, J. S. H., Ishizaki, H., and Hong, J. (1990) Cytochrome P450IIE1: Roles in nitrosamine metabolism and mechanisms of regulation. Drug Metab. Rev. 22, 147–159.
181. Yoo, J. S. H., Ishizaki, H., and Yang, C. S. (1990) Roles of cytochrome P450IIE1 in the dealkylation and denitrosation of N-nitrosodimethylamine and N-nitrosodiethylamine in rat liver microsomes. Carcinogenesis 11, 2239–2243.
182. Ryan, D. E., Koop, D. R., Thomas, P. E., Coon, M. J., and Levin, W. (1986) Evidence that isoniazid and ethanol induce the same microsomal cytochrome P-450 in rat liver, an isozyme homologous to rabbit liver cytochrome P-450 isozyme 3a. Arch. Biochem. Biophys. 246, 633–644.
183. Pantuck, E. J., Pantuck, C. B., and Conney, A. H. (1987) Effect of streptozotocininduced diabetes in the rat on the metabolism of fluorinated volatile anesthetics. Anesthesiology 66, 24–28.
184. Yoo, J. S. H., Cheung, R. J., Patten, C. J., Wade, D., and Yang, C. S. (1987) Nature of N-nitrosodimethylamine demethylase and its inhibitors. Cancer Res. 47, 3378–3383.
185. Koop, D. R. (1990) Inhibition of ethanol-inducible cytochrome P450IIE1 by 3-aminol, 2, 4-triazole. Chem. Res. Toxicol. 3, 377–383.
186. Phillips, J. C., Lake, B. G., Gangolli, S. D., Grasso, P., and Lloyd, A. G. (1977) Effects of pyrazole and 3-aminol, 2, 4-triazole on the metabolism and toxicity of dimethylnitrosamine in the rat. J. Natl. Cancer Inst. 58, 629–633.
187. Fiala, E. S., Kulakis, C., Christiansen, G., and Weisburger, J. H. (1978) Inhibition of the metabolism of the colon carcinogen, azoxymethane, by pyrazole. Cancer Res. 38, 4515–4521.
188. Hunter, A. I., and Neal, R. A. (1975) Inhibition of hepatic mixedfunction oxidase activity in vitro and in vivo by various thionosulfurcontaining compounds. Biochem. Pharmacol. 24, 2199–2205.
189. Wong, L. C. K., Winston, J. M., Hong, C. B., and Plotnick, H. (1982) Carcinogenicity and toxicity of 1, 2-dibromoethane in the rat. Toxicol. Appl. Pharmacol. 63, 155–165.
190. 6-Ethenoadenosine formation, mutagenicity and murine tumor induction as indicators of the generation of an electrophilic epoxide metabolite of the closely related carcinogens ethyl carbamate (urethane) and vinyl carbamate. Carcinogenesis 11, 463–473.
191. 7-guanyl)ethyl]glutathione from ethylene dibromide: Effects of modulation of glutathione and glutathione S-transferase levels and lack of a role for sulfation. Carcinogenesis 11, 419–424.
192. Chieli, E., Saviozzi, M., Puccini, P., Longo, V., and Gervasi, P. G. (1990) Possible role of the Acetone-inducible cytochrome P-450IIE1 in the metabolism and hepatotoxicity of thiobenzamide. Arch. Toxicol. 64, 122–127.
193. Nakajima, T., Wang, R. S., Murayama, N., and Sato, A. (1990) Three forms of trichloroethylenemetabolizing enzymes in rat liver induced by ethanol, phenobarbital, and 3-methylcholanthrene. Toxicol. Appl. Pharmacol. 102, 546–552.
194. Walsh, C. (1979) Enzymatic Reaction Mechanisms, W. H. Freeman, San Francisco.
195. Dahl, G. A., Miller, J. A., and Miller, E. C. (1978) Vinyl carbamate as a promutagen and a more carcinogenic analog of ethyl carbamate. Cancer Res. 38, 3793–3804.
196. Song, B. J., Veech, R. I., and Saenger, P. (1990) Cytochrome P450IIE1 is elevated in lymphocytes from poorly controlled insulindependent diabetics. J. Clin. Endocrinol. Metab. 71, 1036–1040.
197. Perrot, N., Nalpas, B., Yang, C. S., and Beaune, P. H. (1989) Modulation of cytochrome P450 isozymes in human liver, by ethanol and drug intake. Eur. J. Clin. Invest. 19, 549–555.
198. Song, B. J., Veech, R. I., Park, S. S., Gelboin, H. V., and Gonzalez, F. J. (1989) Induction of rat hepatic N-nitrosodimethylamine demethylase by acetone is due to protein stabilization. J. Biol. Chem. 264, 3568–3572.
199. Kim, S. G., and Novak, R. F. (1990) Induction of rat hepatic P450IIE1 (CYP 2E1) by pyridine: Evidence for a role of protein synthesis in the absence of transcriptional activation. Biochem. Biophys. Res. Commun. 166, 1072–1079.
200. Nebert, D. W., Adesnik, M., Coon, M. J., Estabrook, R. W., Gonzalez, F. J., Guengerich, F. P., Gunsalus, I. C., Johnson, E. F., Kemper, B., Levin, W., Phillips, I. R., Sato, R., and Waterman, M. R. (1987) The P450 gene superfamily: Recommended nomenclature. DNA 6, 1–11.
201. Nebert, D. W., Nelson, D. R., Coon, M. J., Estabrook, R. W., Feyereisen, R., Fujii-Kuriyama, Y., Gonzalez, F. J., Guengerich, F. P., Gunsalus, I. C., Johnson, E. F., Loper, J. C., Sato, R., Waterman, M. R., and Waxman, D. J. (1991) The P450 superfamily: Update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol. 10, 1–14.
202. Graves, P. E., Kaminsky, L. S., and Halpert, J. (1987) Evidence for functional and structural multiplicity of pregnenolonel6 αcarbonitrileinducible cytochrome P-450 isozymes in rat liver microsomes. Biochemistry 26, 3887–3894.
203. 6β, (testosterone 6βhydroxylase) mRNAs in rat livers. J. Biochem. 106, 1030–1034.
204. Kitada, M., Kamataki, T., Itahashi, K., Rikihisa, T., Kato, R., and Kanakubo, Y. (1985) Purification and properties of cytochrome P-450 from homogenates of human fetal livers. Arch. Biochem. Biophys. 241, 275–280.
205. Komori, M., Nishio, K., Kitada, M., Shiramatsu, K., Muroya, K., Soma, M., Nagashima, K., and Kamataki, T. (1990) Fetusspecific expression of a form of cytochrome P-450 in human livers. Biochemistry 29, 4430–4433.
206. Wrighton, S. A., Brian, W. R., Sari, M. A., Iwasaki, M., Guengerich, F. P., Raucy, J. I., Molowa, D. T., and Vandenbranden, M. (1990) Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. 38, 207–213.
207. Wrighton, S. A., and Vandenbranden, M. (1989) Isolation and characterization of human fetal liver cytochrome P450HLp2: A third member of the P450III gene family. Arch. Biochem. Biophys. 268, 144–151.
208. Bork, R. W., Muto, T., Beaune, P. H., Srivastava, P. K., Lloyd, R. S., and Guengerich, F. P. (1989) Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. J. Biol. Chem. 264, 910–919.
209. Daujat, M., Pichard, I., Fabre, I., Diaz, D., Maurice, M., Pineau, T., Blanc, P., Fabre, G., Fabre, J. M., Saint Aubert, B., and Maurel, P. (1990) Human P450IA and IIIA subfamilies: Regulation of expression and inducibility in primary cultures of human hepatocytes. In Drug Metabolizing Enzymes: Genetics, Regulation and Toxicology, Proceedings of the Eighth International Symposium on Microsomes and Drug Oxidations (Ingelman-Sundberg, M., Gustafsson, J.-A., and Orrenius, S., Eds.) p 16, Karolinska Institute, Stockholm.
210. Huang, M. T., Johnson, E. F., Muller-Eberhard, U., Koop, D. R., Coon, M. J., and Conney, A. H. (1981) Specificity in the activation and inhibition by flavonoids of benzo[a]pyrene hydroxylation by cytochrome P-450 isozymes from rabbit liver microsomes. J. Biol. Chem. 256, 10897–10901.
211. Yamazoe, Y., Murayama, N., Shimada, M., Yamauchi, K., Nagata, K., Imaoka, S., Funae, Y., and Kato, R. (1988) A sexspecific form of cytochrome P-450 catalyzing propoxycoumarin O-depropylation and its identity with testosterone 6βhydroxylase in untreated rat livers: Reconstitution of the activity with microsomal lipids. J. Biochem. 104, 785–790.
212. Guengerich, F. P., Müller-Enoch, D., and Blair, I. A. (1986) Oxidation of quinidine by human liver cytochrome P-450. Mol. Pharmacol. 30, 287–295.
213. Renaud, J.-P., Cullin, C., Pompon, D., Beaune, P., and Mansuy, D. (1990) Expression of human liver cytochrome P450 IIIA4 in yeast: A functional model for the hepatic enzyme. Eur. J. Biochem. 194, 889–896.
214. Kronbach, T., Mathys, D., Umeno, M., Gonzalez, F. J., and Meyer, U. A. (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol. 36, 89–96.
215. Wang, R. W., Kari, P. H., Lu, A. Y. H., Thomas, P. E., Guengerich, F. P., and Vyas, K. P. (1991) Identification of cytochrome P-450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch. Biochem. Biophys. (in press).
216. Waxman, D. J., Attisano, C., Guengerich, F. P., and Lapenson, D. P. (1988) Cytochrome P-450 steroid hormone metabolism catalyzed by human liver microsomes. Arch. Biochem. Biophys. 263, 424–436.
217. Guengerich, F. P. (1988) Oxidation of l7 αethynylestradiol by human liver cytochrome P-450. Mol. Pharmacol. 33, 500–508.
218. Combalbert, J., Fabre, I., Fabre, G., Dalet, I., Derancourt, J., Cano, J. P., and Maurel, P. (1989) Metabolism of cyclosporin A. IV. Purification and identification of the rifampicininducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug. Metab. Dispos. 17, 197–207.
219. Kronbach, T., Fischer, V., and Meyer, U. A. (1988) Cyclosporin metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporinemetabolizing enzyme explains interactions of cyclosporine with other drugs. Clin. Pharmacol. Ther. 43, 630–635.
220. Schellens, J. H. M., Soons, P. A., and Breimer, D. D. (1988) Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. Biochem. Pharmacol. 37, 2507–2510.
221. Thomson, P. D., Melmon, K. I., Richardson, J. A., Cohn, K., Steinbrunn, W., Cudihee, R., and Rowland, M. (1973) Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann. Intern. Med. 78, 499–508.
222. Park, B. K. (1981) Assessment of urinary 6βhydroxycortisol as an in υiυo index of mixed function oxidase activity. Br. J. Clin. Pharmacol. 12, 97–102.
223. Saenger, P., Forster, E., and Kream, J. (1981) 60-Hydroxycortisol: A noninvasive indicator of enzyme induction. J. Clin. Endocrinol. Metab. 52, 381–384.
224. Edgar, B., Bailey, D. G., Bergstrand, R., Johnsson, G., and Lurje, L. (1990) Formulation dependent interaction between felodipine and grapefruit juice. Clin. Pharmacol. Ther. 47, 181.
225. Morel, F., Beaune, P. H., Ratanasavanh, D., Flinois, J.-P., Yang, C.-S., Guengerich, F. P., and Guillouzo, A. (1990) Expression of cytochrome P-450 enzymes in cultured human hepatocytes. Eur. J. Biochem. 191, 437–444.
226. Delaforge, M., Sartori, E., and Mansuy, D. (1988) In vivo and in vitro effects of a new macrolide antibiotic roxithromycin on rat liver cytochrome P-450: Comparison with troleandomycin and erythromycin. Chem.-Biol. Interact. 68, 179–188.
227. Bailey, D. G., Edgar, B., Spence, J. D., Munzo, C., and Arnold, J. M. O. (1990) Felodipine and nifedipine interactions with grapefruit juice. Clin. Pharmacol. Ther. 47, 180.
228. Booth, A. N., Jones, F. T., and De Eds, F. (1958) Metabolic and glucosuria studies on naringin and phloridzin. J. Biol. Chem. 233, 280–282.
229. 1 by P-450 HFLa in human fetal livers. Mutat. Res. 227, 53–58.
230. Groopman, J. D., Donahue, P. R., Zhu, J., Chen, J., and Wogan, G. N. (1985) Aflatoxin metabolism in humans: Detection of metabolites and nucleic acid adducts in urine by affinity chromatography. Proc. Natl. Acad. Sci. U.S.A. 82, 6492–6496.
231. Kellerman, G., Luyten-Kellerman, M., and Shaw, C. R. (1973) Genetic variation of aryl hydrocarbon hydroxylase in human lymphocytes. Am. J. Hum. Genet. 25, 327–331.
232. Kellerman, G., Shaw, C. R., and Luyten-Kellerman, M. (1973) Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N. Engl. J. Med. 298, 934–937.
233. Paigen, B., Ward, E., Reilly, A., Houten, I., Gurtoo, H. I., Minowada, J., Steenland, K., Havens, M. B., and Sartori, P. (1981) Seasonal variation of aryl hydrocarbon hydroxylase activity in human lymphocytes. Cancer Res. 41, 2757–2761.
234. Kouri, R. E., McKinney, C. E., Slomiany, D. J., Snodgrass, D. R., Wray, N. P., and McLemore, T. L. (1982) Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res. 42, 5030–5037.
235. McLemore, T. I., Adelberg, S., Czerwinski, M., Hubbard, W. C., Yu, S. J., Storeng, R., Wood, T. G., Hines, R. N., and Boyd, M. R. (1989) Altered regulation of the cytochrome P4501A1 gene: Novel inducerindependent gene expression in pulmonary carcinoma cell lines. J. Natl. Cancer Inst. 81, 1787–1794.
236. Jaiswal, A. K., Gonzalez, F. J., and Nebert, D. W. (1985) Human dioxininducible cytochrome P,-450: Complementary DNA and amino acid sequence. Science 228, 80–83.
237. Kawajiri, K., Nakachi, K., Imai, K., Yoshii, A., Shinoda, N., and Watanabe, J. (1990) Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett. 263, 131–133.
238. Tefre, T., Børresen, A.-L., Ryberg, D., Haugen, A., and Brøgger, A. (1990) Allele association studies of the P450IA1 and P450IID1 DNA-polymorphisms in lung cancer patients and controls. In Drug Metabolizing Enzymes: Genetics, Regulation and Toxicology, Proceedings of the Eighth International Symposium on Microsomes, and Drug Oxidations (Ingelman-Sundberg, M., Gustaffson, J.-Å., and Orrenius, S., Eds.) p 51, Karolinska Institute, Stockholm.
239. Brodie, A. M. H. (1985) Aromatase inhibition and its pharmacologic implications. Biochem. Pharmacol. 34, 3213–3219.
240. Wolff, T., Distlerath, L. M., Worthington, M. T., Groopman, J. D., Hammons, G. J., Kadlubar, F. F., Prough, R. A., Martin, M. V., and Guengerich, F. P. (1985) Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. Cancer Res. 45, 2116–2122.
241. 1 catalysed by the same form of cytochrome P-450 as that 4-hydroxylating debrisoquine in rat and/or man? Arch. Toxicol. 58, 165–170.
242. Ritter, J., Somasundaram, R., Heinemeyer, G., and Roots, I. (1986) The debrisoquine hydroxylation phenotype and the acetylator phenotype as genetic risk factors for the occurrence of larynx and pharynx carcinoma. Acta Pharmacol. Toxicol. 59 (Suppl. 5), 221.
243. Drakoulis, N., Minks, T., Ploch, M., Otte, F., Heinemeyer, G., Kampf, D., Loddenkemper, R., and Roots, I. (1986) Questionable association of debrisoquine hydroxilator phenotype and risk for bronchial carcinoma. Acta Pharmacol. Toxicol. 59 (Suppl. 5), 220.
244. Speirs, C. J., Murray, S., Davies, D. S., Mabadeje, A. F. B., and Boobis, A. R. (1990) Debrisoquine oxidation phenotype and susceptibility to lung cancer. Br. J. Clin. Pharmacol. 29, 101–109.
245. Kahn, G. C., Boobis, A. R., Brodie, M. J., Toverud, E. I., Murray, S., and Davies, D. S. (1985) Phenacetin O-deethylase: An activity of a cytochrome P-450 showing genetic linkage with that catalysing the 4-hydroxylation of debrisoquine? Br. J. Clin. Pharmacol. 20, 67–76.
246. Eichelbaum, M., Baur, M. P., Dengler, H. J., Osikowska-Evers, B., Tieves, G., Zekorn, C., and Rittner, C. (1987) Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22. Br. J. Clin. Pharmacol. 23, 455–458.
247. l6α) in mice: Organization, differential regulation, and chromosome localization. J. Biol. Chem. 264, 2920–2927.
248. Poland, A., Glover, E., and Taylor, B. A. (1987) The murine Ah locus: A new allele and mapping to chromosome 12. Mol. Pharmacol. 32, 471–478.
249. Cobb, R. R., Stemming, T. A., and Whitney, J. B., III (1987) The aryl hydrocarbon hydroxylase Ah locus and a novel restrictionfragment length polymorphism (RFLP) are located on mouse chromosome 12. Biochem. Genet. 25, 401–413.
250. Yamazaki, H., Degawa, M., Funae, Y., Imaoka, S., Inui, Y., Guengerich, F. P., and Shimada, T. (1990) Roles of different cytochrome P450 enzymes in bioactivation of the potent hepatocarcinogen 3-methoxy-4-aminoazobenzene by rat and human liver microsomes. Carcinogenesis 12, 133–139.
251. Yasumori, T., Murayama, N., Yamazoe, Y., Nogi, Y., Fukasawa, T., and Kato, R. (1989) Expression of a human P-450IIC gene in yeast cells using galactoseinducible expression system. Mol. Pharmacol. 35, 443–449.
252. Lin, D. X., Malaveille, C., Park, S. S., Gelboin, H. V., and Bartsch, H. (1990) Contribution of DNA methylation and benzylation to N-nitroso-N-methylamineinduced mutagenesis in bacteria: Effects of rat liver cytochrome P450 isozymes and glutathione transferases. Carcinogenesis 11, 1653–1658.
253. Lee, M., Ishizaki, H., Brady, J. F., and Yang, C. S. (1989) Substrate specificity and alkyl group selectivity in the metabolism of N-nitrosodialkylamines. Cancer Res. 49, 1470–1474.
254. Searle, C. E., Ed. (1984) Chemical Carcinogens, Vols. 1 and 2, American Chemical Society, Washington, DC.
255. Poulos, T. I., Finzel, B. C., Gunsalus, I. C., Wagner, G. C., and Kraut, J. (1985) The 2.6-Â crystal structure of Pseudomonas putida cytochrome P-450. J. Biol. Chem. 260, 16122–16130.
256. Lewis, D. F. V., Ioannides, C., and Parke, D. V. (1987) Structural requirements for substrates of cytochromes P-450 and P-448. Chem.-Biol. Interact. 64, 39–60.
257. van Biederen, P. J., Armstrong, R. N., Cobb, D., Thakker, D. R., Ryan, D. E., Thomas, P. E., Sharma, N. D., Boyd, D. R., Levin, W., and Jerina, D. M. (1982) Stereoselective formation of benz-[α]anthracene (+)-(5S, 6R)-oxide and (+)-(8R, 9S)-oxide by a highly purified and reconstituted system containing cytochrome P-450c. Biochem. Biophys. Res. Commun. 106, 602–609.